IMPACT OF SEMAGLUTIDE USE ON LEAN MASS AND SARCOPENIA RISK: AN INTEGRATIVE REVIEW OF CLINICAL EVIDENCE
Authors:
- Valéria Goulart VianaVVValéria Goulart Viana
- Juan del Castillo NunesJNJuan del Castillo Nunes
- Jessica Regina GiacomelliJGJessica Regina Giacomelli
- Luan Caimar FuchsLFLuan Caimar Fuchs
- Fellipe Juvele ZampolliFZFellipe Juvele Zampolli
- Mauro Oliveira DiasMDMauro Oliveira Dias
- Gabrielly Kaiumy OtaniGOGabrielly Kaiumy Otani
- Eric Tubertini MinamiEMEric Tubertini Minami
- Stuart Gonçalves da SilvaSSStuart Gonçalves da Silva
- Sophia Veiga BianchiniSBSophia Veiga Bianchini
- André Gustavo Sampaio CostaACAndré Gustavo Sampaio Costa
- Edilson Soares da Silva JuniorEJEdilson Soares da Silva Junior
Open Access
- 24 February 2026
- book chapter
- Published by Seven Events
- p. 416-427
Abstract
Semaglutide has emerged as an effective pharmacological strategy for the management of obesity and type 2 diabetes mellitus, promoting significant weight loss. However, its effects on lean mass, muscle function, and the risk of sarcopenia remain under debate, particularly in vulnerable populations such as older adults. The aim of this study was to critically analyze the available clinical evidence regarding the impact of semaglutide on lean mass and sarcopenia risk. This narrative review was conducted based on systematic searches in the PubMed/MEDLINE, SciELO, and ScienceDirect databases, including studies published between 2015 and 2025. Randomized clinical trials, observational studies, and retrospective cohorts conducted in humans that assessed the effects of semaglutide on body composition, lean mass, and sarcopenia-related functional outcomes were included. A total of 19 studies were analyzed. Semaglutide was consistently associated with significant weight loss, primarily driven by fat mass reduction. An absolute reduction in lean mass was observed; however, it was proportionally smaller relative to total weight loss, resulting in a favorable redistribution of body composition. Muscle function outcomes were heterogeneous, with functional preservation in non-elderly adults and a higher risk of functional decline in older and clinically vulnerable populations. In conclusion, semaglutide promotes favorable changes in body composition; however, its effects on lean mass and muscle function are highly dependent on patient characteristics. Although no direct causal relationship with sarcopenia has been established, monitoring of muscle mass and function is recommended, particularly in older adults, along with integrated strategies such as resistance training and adequate protein intake to mitigate potential musculoskeletal risks.Keywords
This publication has 9 references indexed in Scilit:
- Metabolic and structural remodeling during browning of primary human adipocytes derived from omental and subcutaneous depotsObesity, 2023
- The Interactive Role of Sleep and Circadian Rhythms in Episodic Memory in Older AdultsThe Journals of Gerontology, Series A: Biological Sciences and Medical Sciences, 2023
- Integrated safety and efficacy analysis of dasiglucagon for the treatment of severe hypoglycaemia in individuals with type 1 diabetesDiabetes, Obesity and Metabolism, 2023
- Among biomarkers of neutrophil activity, matrix metalloproteinases 8 independently predicts remission of metabolic syndromeNutrition, Metabolism and Cardiovascular Diseases, 2022
- Clinical evaluation of the new indirect calorimeter in canopy and face mask mode for energy expenditure measurement in spontaneously breathing patientsClinical Nutrition, 2022
- Superiority of focused ion beam‐scanning electron microscope tomography of cardiomyocytes over standard 2D analyses highlighted by unmasking mitochondrial heterogeneityJournal of Cachexia, Sarcopenia and Muscle, 2021
- Once-Weekly Semaglutide in Adults with Overweight or ObesityNew England Journal of Medicine, 2021
- Sarcopenia: revised European consensus on definition and diagnosisAge and Ageing, 2018
- Attenuation of skeletal muscle and strength in the elderly: The Health ABC StudyJournal of Applied Physiology, 2001